ProShares Ultra Nasdaq Biotechnology
$112.01−5.15 (−4.40%)
- Expense ratio
- 1.19%
- Fund size
- $93M
- 1Y return
- +100.7%
- Yield · Last 12 months
- 0.28%
- Holdings
- 274
- Volume · 30D
- 0M sh
- NAV per share
- $110.99
- 52W range
The ETF.net BIB Grade
Score 54 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.DScore 32Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 67Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.AScore 81Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.CScore 52Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 75Category rank
Our read on BIB
CBiotech with the volume turned up. BIB aims for twice the daily move of the Nasdaq Biotechnology Index, about 300 drug and gene names deep, and has run that playbook since 2010. The daily reset means holding period is the whole game.
The Fund seeks daily investment results, before fees and expenses, that correspond to two times the daily performance of the Nasdaq Biotechnology Index.
Why people hold it
- Twice the daily move of the Nasdaq Biotechnology Index, spread across roughly 300 biotech and pharma names instead of one binary trial readout.
- Two times daily, not three: a lower gear than the 3x products that crowd the leveraged shelf.
- Launched in 2010, a long run for a geared fund and one of the older ways to trade biotech with leverage.
- Lands in the upper half of its leveraged-bull peer group, helped by a milder risk profile than most funds carrying daily gearing.
Worth knowing
- Daily reset: the 2x target applies to one day at a time. Over longer holds, compounding can pull results away from twice the index's cumulative move, especially in choppy markets.
- 1.19% a year, above the typical leveraged fund's fee, and the drag compounds the longer the position sits.
- Trades thinly next to marquee geared names like QLD and FAS, so spreads and limit orders carry more weight here.
BIB Holdings
- Stocks
- 274
- 68%
- Net Other Assets (Liabilities)
Sectors
- Health Care74.3%
- Financials25.7%
Geography
- United States90.94%
- United Kingdom1.97%
- Netherlands1.78%
- Ireland1.27%
- Denmark0.94%
- Switzerland0.85%
- France0.84%
- Germany0.57%
- 0.83%
BIB Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | BIB |
|---|---|
| Year to date | +46.9% |
| 1 month | −4.1% |
| 3 months | +33.1% |
| 1 year | +100.7% |
| 3 years | +35.9% |
| 5 years | +3.0% |
| 10 years | +8.7% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | BIB |
|---|---|---|
| 2026 YTD | +46.9% | |
| 2025 | +59.2% | |
| 2024 | −9.8% | |
| 2023 | −1.1% | |
| 2022 | −28.8% | |
| 2021 | −6.0% | |
| 2020 | +39.8% |
BIB in the news
ETF.net Research hasn’t filed on BIB yet — coverage lands here as it’s written.
BIB Dividends
- 0.28%
- $0.32
- $0.0071 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Mar 25, 2026 | Mar 31, 2026 | $0.0071 |
| Dec 24, 2025 | Dec 31, 2025 | $0.13 |
| Sep 24, 2025 | Sep 30, 2025 | $0.18 |
| Jun 25, 2025 | Jul 1, 2025 | $0.17 |
| Mar 26, 2025 | Apr 1, 2025 | $0.13 |
| Dec 23, 2024 | Dec 31, 2024 | $0.40 |
| Sep 25, 2024 | Oct 2, 2024 | $0.15 |
| Jun 26, 2024 | Jul 3, 2024 | $0.26 |
| Mar 20, 2024 | Mar 27, 2024 | $0.04 |
| Dec 20, 2023 | Dec 28, 2023 | $0.04 |
| Dec 22, 2022 | Dec 30, 2022 | $0.02 |
| Sep 21, 2010 | Sep 28, 2010 | $0.01 |
BIB Risk
This fund targets a multiple of the daily move of its index and resets daily. Hold it longer than one reset and compounding makes the return diverge from that target. In choppy markets it can lose value even when the index ends flat.
- 35.8%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.82
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −64.8%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.22
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
BIB Cost
- The middle half of Leveraged Long (2x & Other) funds
- Median 0.99%
65 of the 93 Leveraged Long (2x & Other) funds charge less.